logo
We Might Finally Know How The Brain Refreshes Itself at Night

We Might Finally Know How The Brain Refreshes Itself at Night

Yahoo27-01-2025

As you lay your head down to sleep tonight and dream all things weird and wonderful, scientists think your brain is going through a gentle rinse cycle, washing away a day's worth of toxic by-products in preparation for a new day of thinking ahead.
But the mechanisms behind this neurological cleansing system have yet to be described in detail.
Now researchers from the University of Copenhagen have applied a suite of technologies to map the subtle rise and fall of neurotransmitters, blood volume, and spinal fluid in mice as they go about their day.
The findings don't only help us understand better how the brain refreshes itself at night, they also reveal a surpise downside to common sleep drugs like Ambien.
Colorfully described as the brain's 'sewage network', the biological plumbing technically referred to as the glymphatic system is an anatomical novelty in many respects, having only been identified in mice a little over a decade ago.
Ongoing investigations have since mapped the network in human brains, revealing the glymphatic system draws spinal fluid deep into the brain's interior to carry away materials that risk causing damage in high concentrations. Some of these waste products are linked to Alzheimer's disease.
This 'sewage removal' also helps balance water levels across the brain, facilitates the presentation of potentially dangerous agents of disease to the immune system, and even helps deliver supplies of fuel to where it's needed most.
Studies on how the brain ejects material into the waste removal system to be rhythmically washed away for removal suggest brain wave patterns orchestrated collectively by neurons coordinate the process. Yet they typically rely on anesthetized animal models, leaving questions on how a naturally-occurring sleep-wake cycle manages its glymphatic system.
What's more, some have begun to challenge some of the fundamental assumptions of the process, such as whether it's truly a sleep-dependent exercise at all.
"The motivation for this research was to better understand what drives glymphatic flow during sleep, and the insights from this study have broad implications for understanding the components of restorative sleep," says Maiken Nedergaard, senior author and co-director of the University of Rochester's Center for Translational Neuromedicine.
To trace the brain-washing process back to its physiological roots, researchers developed a new method of fiber optic implants which allowed them to record the dynamics of fluids through the brains of mice as the animals ran relatively free about their cages.
By tagging the neurotransmitter norepinephrine and using the fibre optic implant to activate light-sensitive genes engineered into the animal's brain tissues, the team could monitor and experiment on fluctuations in waste removal while the mice were asleep and while they were awake.
The researchers' work supported earlier studies showing norepinephrine caused blood vessels to contract rhythmically over pulses lasting around 50 seconds, followed by a subtle oscillation in blood volume throughout the brain.
This relationship between neurotransmitter fluctuations and changing blood volumes was far more pronounced while the mice were in a non-dreaming sleep state than awake or in a dream-phase.
Furthermore, they demonstrated experimentally these pulsations did, in fact, drive the glymphatic system into penetrating further into the brain, affirming the role deep sleep plays in clearing out the garbage left by a day's hard thinking.
"These findings, combined with what we know about the glymphatic system, paint the whole picture of the dynamics inside the brain, and these slow waves, micro-arousals, and the norepinephrine were the missing link," says the study's first author, neuroscientist Natalie Hauglund.
Not just any old sleep will do, either. Inspired by claims that sleep-aid pharmaceuticals like Zolpidem – sold as Ambien – can alter sleep phases, the research team tested what impact, if any, the drug had on the cleaning process, finding it reduced the oscillations and impeded the ability for cerebrospinal fluid to work its way into the brain's depths.
Translating the work to humans will rely on further experiments, though it's a safe bet our brains behave in relatively similar ways.
This doesn't mean sleep medication doesn't have its place, though knowing it comes with a potential cost to our ability to hose out each day's neurological scraps might weigh into future decisions on the best ways to keep our brains healthy.
This research was published in Cell.
Expert Reveals Why The FDA Finally Banned 'Red 3' Dye
'Forever Chemicals' in US Drinking Water Linked to Cancer, Scientists Find
Study Reveals 2 Key Ways to Reduce Fatigue at Work

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference
Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

Yahoo

time4 hours ago

  • Yahoo

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

LEXINGTON, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced Alfred W. Sandrock, Jr., M.D., Ph.D., Chief Executive Officer of Voyager, and additional members of management will participate in a pre-recorded fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference. An on-demand webcast of the pre-recorded fireside chat will be available and may be accessed from the Investors section of Voyager's website at starting at 7:00 a.m. ET on June 17, 2025. The on-demand webcast will be archived on the Company's website for at least 30 days. About Voyager TherapeuticsVoyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology company dedicated to leveraging the power of human genetics to modify the course of – and ultimately cure – neurological diseases. Our pipeline includes programs for Alzheimer's disease, Friedreich's ataxia, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and multiple other diseases of the central nervous system. Many of our programs are derived from our TRACER™ AAV capsid discovery platform, which we have used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Some of our programs are wholly owned, and some are advancing with partners including Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; and Neurocrine Biosciences, Inc. For more information, visit Voyager Therapeutics® is a registered trademark, and TRACER™ is a trademark, of Voyager Therapeutics, Inc. ContactsTrista Morrison, tmorrison@ Investors: Sarah McCabe, smccabe@ Brooke Shenkin, brooke@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

1 in 10 Hoosiers over 65 has Alzheimer's
1 in 10 Hoosiers over 65 has Alzheimer's

Axios

time5 hours ago

  • Axios

1 in 10 Hoosiers over 65 has Alzheimer's

Nearly 11% of Hoosiers over 65 are living with Alzheimer's — more than 121,300 people — according to 2020 data shared in a new Alzheimer's Association report. Why it matters: More than 7 million American seniors now live with Alzheimer's, the highest number ever recorded, but addressing cognitive decline early can help stave off the disease. By the numbers: Almost two-thirds of Americans with Alzheimer's are women, per data cited in the report. Risk increases with age: 5.1% of people ages 65–74 have it, while a third of people 85 and older have it, per the report. Zoom in: Indiana's elderly population is expected to grow rapidly in the coming years, according to projections from the Indiana Business Research Center at Indiana University's Kelley School of Business. One in every five Hoosiers (over 966,000 people) will be 65 or older by 2030. Marion County skews a bit younger. The elderly population percentage is here is poised to reach 16.2% in 2030. Stunning stat: The research center says the number of people 65 and up in Indiana will surpass 1.5 million by 2050, a 57% increase from 2015. Threat level: Nearly 18% of Hoosiers 45 and older already have subjective cognitive decline, according to the Alzheimer's Association. And the burden of care is often thrust onto family members. The Alzheimer's Association estimates about 219,000 Indiana caregivers provide unpaid care valued at $6.9 billion for loved ones with the disease. Zoom out: The highest rates of seniors with Alzheimer's are in D.C. (16.8%) and Maryland (12.9%). The lowest is in Alaska (8.8%). What they're saying: "It doesn't surprise me" that Alzheimer's incidence has increased, because the population is aging and "we're becoming more sophisticated in our options for diagnosing and testing for Alzheimer's disease," Lakelyn Eichenberger, a gerontologist and caregiving advocate at Home Instead, tells Axios. With cases climbing and age a key risk factor, early action is critical for managing the disease and accessing new treatments, Eichenberger says. Warning signs to watch for in high-risk age groups: Trouble finding the right word. Difficulty judging distances. Misplacing things and struggling to retrace steps. Between the lines: "If you're seeing patterns of these types of signs over an extended period of time," that could mean it's time to see a doctor about cognitive decline, Eichenberger says.

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease
AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Yahoo

time12 hours ago

  • Yahoo

AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease

Seongnam-si, South Korea and Abu Dhabi, UAE, June 09, 2025 (GLOBE NEWSWIRE) -- AriBio Co., Ltd. ("AriBio"), a South Korean biopharmaceutical company specializing in neurodegenerative diseases, and a Swiss pharmaceutical company Acino, part of Arcera, a global life sciences company based in Abu Dhabi (collectively 'Arcera'), today announced the signing of exclusive licensing and commercialization, and supply agreements for AR1001, an investigational oral therapy for Alzheimer's disease. Under the terms of the agreements, Arcera will have exclusive rights to commercialize AR1001 in its key markets, including Latin America, the Middle East, Southern Africa, Ukraine and select Eurasian countries. AriBio will be responsible for manufacturing and supplying the product. The total deal value is estimated at USD 600 million across the development, launch and commercialization period, contingent upon the achievement of certain milestones. AR1001 is a novel, disease-modifying, once-daily oral phosphodiesterase-5 (PDE5) inhibitor currently being studied in a global Phase 3 clinical trial (POLARIS-AD) for the treatment of early-stage Alzheimer's disease. The enrollment target for the Phase 3 trial has been reached, and the topline results are expected in the first half of 2026. Facilitated by the Korea Development Bank (KDB) and aligned with the Korean government's policy to foster the biohealth industry, this collaboration represents a significant step forward to enhance the global competitiveness of Korea's pharmaceutical and biotech industry. "This partnership with Arcera marks a significant milestone in our mission to bring innovative treatments to patients worldwide," said Jai Jun Choung, CEO of AriBio. "Arcera's strong commercial capabilities and deep understanding of the high-growth markets make them an ideal partner to advance AR1001 in these important regions." "We are excited to enter into this collaboration with AriBio, which will provide access to AR1001, a novel treatment, for patients across these countries," said Isabel Afonso, CEO of Arcera. "This agreement aligns with our strategy to expand our neuroscience portfolio and reinforces our commitment to providing access to novel therapies in regions with significant unmet medical needs." The agreement underscores both companies' dedication to addressing unmet medical needs in neurodegenerative diseases and enhancing patient access to innovative therapies globally. This deal follows the Memorandum of Understanding signed between AriBio and Arcera in March 2025, where both parties agreed to strengthen their partnership by actively exploring strategic investments, and advancing joint research and development based on shared interests. ENDS About AriBio Co., Ltd. Founded in 2010, AriBio is a clinical-stage biopharmaceutical company headquartered in South Korea, with offices located in the United States to manage global clinical operations and regulatory affairs. The company focuses on the development of novel therapies for neurodegenerative diseases, including Alzheimer's disease. AriBio continues to expand its partnerships to accelerate the development and delivery of life-changing treatments to patients worldwide. About Arcera Arcera is a global life sciences company, headquartered in Abu Dhabi. Arcera develops, manufactures, and commercializes a broad range of high-quality proven and innovative medicines in key international markets. Its portfolio exceeds 2,000 medicines covering wide therapeutic areas which reach patients in ninety countries in four continents, backed by manufacturing and packing sites across the world. Arcera was established by the sovereign wealth fund, ADQ to realize Abu Dhabi's ambition as a global leader in innovative and sustainable healthcare. To learn more about Arcera, visit Attachment AriBio and Arcera Sign Exclusive Licensing and Supply Agreements for Investigational Drug for Alzheimer's Disease CONTACT: Tanya Xi, MD, PhD, MBA, Senior Director, Business Development & Medical Affairs, AriBio (US) AriBio Co., Ltd. tanyaxi@ Rafael Ferrer, SVP Corporate Development. Arcera rferrer@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store